Plain-English translation of NCT06800963 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This trial is testing a new medication called recombinant Mycobacterium BCG (rMBCG) for people with early-stage bladder cancer. The medication is delivered directly into the bladder through a catheter. Researchers want to see if this new version works well and is safe for patients who haven't previously received standard BCG treatment.
Standard BCG therapy has been used for bladder cancer for decades, but some patients don't respond well or can't tolerate it. This trial exists to see if a genetically modified version of BCG might be more effective or better tolerated as a new option for these patients.
You likely qualify if…
You likely don't qualify if…
You would receive an induction course of the new medication delivered into your bladder through a catheter—a thin tube inserted through the urethra. The study involves multiple visits to the clinic for treatment and monitoring, with blood tests and bladder exams to check how well the treatment is working and whether you're experiencing any side effects. The exact duration and number of treatments will be determined by the research team.
AI-generated summary from trial data · Jun 4, 2026 · Not medical advice
United States